TA demonstrates non-inferior oncological efficacy compared to CND for strictly selected patients with recurrent low-burden lymph node metastasis, offering minimally invasive, risk-adaptive therapeutic strategies with superior procedural efficiency and quality-of-life benefits.
Ye et al. (Thu,) studied this question.